SHANGHAI, Aug. 1, 2025 /PRNewswire/ — Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911, has received Investigational New Drug (IND) application acceptance from China’s National Medical Products Administration (NMPA) and an IND Acknowledgement Letter from the U.S. Food and Drug Administration (FDA).

7MW4911 is an investigational CDH17-targeting ADC developed using Mabwell’s proprietary IDDC™ platform. Its highly optimized structure integrates three key elements:

• Mab0727: A highly specific CDH17 monoclonal antibody with rapid internalization properties, cross-species (human/monkey) moderate affinity, and minimal off-target binding.
• Novel cleavable linker: Ensures precise payload release in tumor tissues.
• MF-6 payload: A proprietary DNA topoisomerase I inhibitor designed to overcome multidrug resistance (MDR), exhibiting superior plasma stability, controlled drug release, and potent bystander effects.

In July 2025, Mabwell published preclinical data in Cell Reports Medicine (“Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor”), demonstrating 7MW4911’s tumor-selective cytotoxicity via CDH17-mediated internalization. Key advantages include:

• Optimized molecular design: Homogeneous drug-to-antibody ratio (DAR=4, >95%) and stable linker confer exceptional plasma stability, while membrane-permeable MF-6 drives potent bystander killing.
• Broad Antitumor Efficacy: Demonstrates robust tumor regression in colorectal, gastric, and pancreatic cancer PDX/CDX models, including tumors with RAS/BRAF mutations and diverse Consensus Molecular Subtypes (CMS).
• MDR resistance: Outperforms MMAE/DXd-based ADCs in ABC transporter-mediated MDR models and reverses tumor progression post-ADC treatment.
• Target versatility: Active even in tumors with low-to-moderate CDH17 expression, expanding potential patient eligibility.
• Favorable safety profile: Limited tissue distribution in mice, controllable pharmacokinetics (moderate half-life, no accumulation), and a wide therapeutic window in cynomolgus monkeys, with no significant toxicity signals.

With this profile, 7MW4911 emerges as a promising therapeutic candidate for advanced gastrointestinal cancers.

About CDH17

CDH17 is a pan-cancer validated target with restricted expression in normal intestinal epithelium but marked overexpression in gastrointestinal cancers (e.g., colorectal, gastric, pancreatic). Its aberrant expression correlates with tumor metastasis and poor prognosis, positioning it as an ideal therapeutic target.

About Mabwell

Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. The company provides more effective and accessible therapy and innovative medicines to fulfill global medical needs, focusing on oncology and aging-related disease indications. Mabwell’s mission is “Explore Life, Benefit Health” and its vision is “Innovation, from ideas to reality”. For more information, please visit www.mabwell.com/en.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company’s product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. “Forward-looking statements” are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions and the negatives of those terms.

Forward-looking statements are based on the Company’s current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company’s control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the potential impact of COVID-19; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.

The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.

GUANGZHOU, China, Aug. 1, 2025 /PRNewswire/ — GAC’s global expansion is accelerating in recent years. As Chinese automakers emerge as global trendsetters in market scale, technological innovation and talent attraction, GAC stands at the forefront of this transformation. In this exclusive interview, Masato Katsumata – GAC INTERNATIONAL’s Chief Technology Officer explains why he chose to join GAC, while his endorsement reinforces GAC’s position as the focal point of China’s automotive globalization. In addition, he also discusses the evolution of vehicle technology, from traditional engines to new energy and AI-driven advancements, emphasizing a user-centric approach and the ultimate pursuit of detail.

With the “One GAC 2.0” strategy that blends world-class technology with deep local market insights, GAC is redefining what it means to be a truly global automaker. Industry engineers like Katsumata are betting on GAC’s vision – where he hopes that as a world-class enterprise, GAC is committed to going global in multiple aspects, driven by cutting-edge technology and a mission to deliver excellence worldwide.

– Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%.

– I-Mab’s Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated an impressive overall response rate (ORR) of 83% in combination with immunotherapy in a Phase 1b trial of first line gastric cancers.

– I-Mab’s differentiated 4-1BB receptor targeting platform and bispecific antibody pipeline are highly complementary with the Company’s existing mRNA cancer vaccines and in vivo CAR-T platform.

– Complementary and synergistic clinical development and business development platforms, especially I-Mab’s unique clinical translational capabilities, particularly in the U.S., and Everest’s clinical capabilities in Asia, could help accelerate the development and global expansion of pipeline products for both companies.

–  New investors in this offering also include Janus Henderson Investors, Adage Capital Partners LP, Woodline Partners, and Exome Asset Management

SHANGHAI, Aug. 1, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has made a strategic equity investment in I-Mab, (”I-Mab”), a company listed on the Nasdaq Global Market (”Nasdaq”) trading under the symbol ”IMAB”.

“This strategic equity investment furthers our plan to be an active player in next-generation oncology programs across global markets. Everest and its Board of Directors believe this investment recognizes I-Mab’s unique clinical translational capabilities in the U.S., which are complementary and synergistic with the Company’s strong Asia presence,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “As a biotech pioneer in China, Everest has built internally developed pipeline assets including mRNA therapeutic cancer vaccines and in vivo CAR-T therapies targeting cancer and autoimmune diseases. Our areas of focus meaningfully intersect with I-Mab’s differentiated 4-1BB platform and bispecific antibody pipeline, including oncology candidates Givastomig (Claudin 18.2 x 4-1BB bispecific antibody) and Ragistomig (PD-L1 x 4-1BB bispecific antibody), both promising programs that we are closely watching. Furthermore, both companies may be able to leverage their combined expertise to run clinical programs in both China and the U.S. Everest is proud to develop innovative and valuable therapies that can benefit cancer patients globally.”

Financial Terms and Corporate Updates:

I-Mab today announced an underwritten offering of 33,333,334 American Depositary Shares (the “ADSs”) representing 76,666,668 ordinary shares at an offering price of $1.95 per ADS, for total gross proceeds of approximately US$65 million. Under the arrangement of this offering, Everest will subscribe for 15,846,154 ADSs (the “Subscription”), with an aggregate consideration of US$30.9 million. Upon completion of the Subscription, the Company shall hold an aggregate of 15,846,154 ADSs and 6,078,571 ordinary shares, representing approximately 16.1% of the total issued share capital of I-Mab, inclusive of 6,078,571 ordinary shares already held by Everest.

As all of the applicable percentage ratios of the Subscription are less than 5%, the Subscription is not subject to the announcement or shareholders’ approval requirements under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The investment in I-Mab shares is expected to be booked as “investments” under non-current assets on Everest’s balance sheet. Changes from “mark-to-market” are expected to be reflected in fair value through other comprehensive income in the statement of changes in equity and the investment has no impact on the Company’s P/L statement and will not appear as an operating expense.

I-Mab is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. There are three pipeline products of I-Mab in clinical stage, Givastomig (Claudin 18.2 x 4-1BB bispecific antibody), Ragistomig (PD-L1 x 4-1BB bispecific antibody) and Uliledlimab (CD73 antibody).

I-Mab recently presented positive Phase 1b dose escalation results for givastomig in combination with immunotherapy in first line gastric cancer (ORR of 83%) at the ESMO GI 2025 conference which are summarized here.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders.

For more information, please visit its website at www.everestmedicines.com.

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first line metastatic gastric cancers, with additional potential in other solid tumors. In ongoing Phase 1 trials, givastomig has been observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents.

For more information, please visit www.i-mabbiopharma.com and follow us on LinkedIn and X.

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

LOS ANGELES, Aug. 1, 2025 /PRNewswire/ — Insta360 today announced official Strava compatibility for its popular Stats Dashboard feature, giving cyclists and outdoor athletes a powerful new way to visualize real-time performance data directly within their videos.

What Is Insta360’s Stats Dashboard?

Offered as a built-in feature right within Insta360’s editing suite in the app, add real-time data overlays—like speed, incline, cadence, and heart rate—directly onto footage from some of Insta360’s best selling cameras, including the 360-capture X series, point-and-shoot Ace Pro 2, GO 3S, and more.

Previously, creating data-driven edits required advanced post-production software and manual syncing on desktop. Now, creators can generate polished, professional-looking overlays entirely on mobile, simply by importing their video and syncing it with data from wearables or GPS devices.

Integrating with the Best in Fitness Tracking

Until now, the Stats Dashboard only supported data from brand-specific platforms like Apple or Garmin. This fragmented approach made it difficult to reach users across the broader fitness community.

With Strava, one of the world’s most popular cycling and fitness tracking platforms, now acting as a universal data source, creators can automatically sync data from their Strava-connected devices (Apple Watch, Garmin, etc.) into the Insta360 app with just a few taps.

This update removes the need for manual file transfers or device-matching and opens the door for creators to bring a more dynamic, personalized element into their sports videos.

Benefits for Creators and Athletes

Hitting a group weekend ride or tracking your daily workouts with a twist, the Stats Dashboard with Strava support helps bring your footage to life.

Immersive storytelling shows precisly your effort, speed bursts, and elevation gain directly in videos.
Streamlined editing makes producing immersive, data-driven videos easier than ever, cutting edit time.
Audience engagement is higher than ever, as data-driven content typically performs better on social platforms and strengthens community connection.

Availability

Strava compatibility is now available to all users, so long as users have updated their Insta360 app to version v2.6.0 or above (iOS or Android). Try out this new integration today and share immersive shots seamlessly with your training community.

About Insta360

With a “Think bold” mindset, Insta360 empowers people to capture and share their lives in extraordinary ways. Recognized as a market leader and innovator, Insta360’s vast lineup includes the world’s best-selling 360° cameras in the X Series, the thumb-sized GO Series for everyday capture, as well as an extensive range of action cameras, gimbals, webcams, and professional photography solutions. With intuitive, AI-powered software, Insta360 simplifies the creative process, allowing users to focus on storytelling without technical barriers. Insta360 is dedicated to helping a new generation of athletes, creatives, travelers and professionals bring their ideas to life.

For more details visit: http://www.insta360.com
About the Think Bold Fund: https://www.insta360.com/ThinkBoldFund
Read our blog: https://www.insta360.com/blog
Follow us on Facebook: https://www.facebook.com/Insta360
Follow us on X: https://x.com/insta360 
Follow us on Instagram: http://www.instagram.com/insta360
Follow us on TikTok: http://tiktok.com/@insta360_official
Follow us on LinkedIn: https://www.linkedin.com/company/insta360
Subscribe to our YouTube Channel: http://www.youtube.com/insta360

Press Contact
Max Richter
Insta360
pr@insta360.com